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OBJECTIVES: Thyroid dysfunction is the second most common endocrinopathy 
affecting women of childbearing age. Many studies have recommended that 
thyroid function screening should be routinely performed in all pregnant 
women. The aim of the present study was to determine the prevalence of thyroid 
disorders during pregnancy and to evaluate efficiency of the universal screening 
strategy versus case-finding strategy for diagnosing thyroid dysfunctions. 
METHODS: Comprehensive literature search was done in PubMed and EMBASE 
databases till July 2012 for studies related to prevalence and screening of thyroid 
dysfunction. For prevalence, the primary estimate was weighed mean pooled 
prevalence (%) with 95% CI. For screening, the primary estimate was pooled odds 
ratio (OR) with 95% CI. Heterogeneity was assessed by I2 statistics. Publication 
bias was assessed using Begg and Egger test. Sensitivity analysis was also 
performed. RESULTS: A total of 33 studies (1988- 2012) for prevalence and 5 
(2007- 2011) for screening were found to be pertinent. Because of significant 
heterogeneity, a random effects model was chosen. Combined analysis of 
weighed pooled prevalence of 19 studies of Thyroid Auto Immunity found 9.7% 
(9.5-10), 21 studies of hypothyroidism found 3.7% (2.2-6.1) and 10 studies of 
hyperthyroidism found 2.2% (1.0-4.5), 7 studies of overt/ clinical hypothyroidism 
found 2% (0.8-5.1), 13 studies of subclinical hypothyroidism found 3.7% (3-4.7), 6 
studies of hypothyroxinemia found 3.4% (1.2-9.8), 4 studies of overt/ clinical 
hyperthyroidism found 0.6% (0.3-1.4) and 5 studies of subclinical 
hyperthyroidism found 0.022 (1.6-2.9). For the effectiveness of universal 
screening pooled OR was found to be 2.87 (1.60-4.94, P-<0.001). CONCLUSIONS: 
Our analysis supports the hypothesis of higher prevalence of thyroid dysfunction 
in pregnancy especially, hypothyroidism. The universal screening strategy is 
found to be more effective as the case-finding strategy fails to detect the 
majority of pregnant women with thyroid dysfunction.  
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OBJECTIVES: Hyponatremia (HN) is the most common electrolyte abnormality in 
hospitalized patients. Because of the methodological difficulties, little is known 
regarding the impact and management of HN on patient outcomes and health 
care resource usage. The HN Registry is a novel prospective effort to document 
the clinical management and health care outcomes of HN. METHODS: After 
informed consent or waiver, data were extracted from medical charts of patients 
enrolled in the HN registry. HN was defined as a serum sodium ≤ 130 mmol/L. 
Data from these eligible patients are summarized by sample size (n) and 
percentage (%) for categorical data, and mean and standard deviation for 
continuous data. Since there is no universal definition, length of stay (LOS) was 
calculated in several ways including LOS from date of HN identification (LOS 1), 
LOS from date of HN treatment initiation (LOS 2), and LOS limited to cases where 
treatment started within 2 days of HN identification (LOS 3). RESULTS: A total of 
3795 of the 4909 patients enrolled at 253 (US=160, EU=93) sites between Sept 2010 
and January 2013 had sufficient data for analysis. For fluid restriction, LOS 
1=8.1±8.4, LOS 2=7.4±8.9, LOS 3=7.4±9.0. For pharmacological therapy, LOS 
1=8.7±8.9, LOS 2=7.1±8.2, LOS 7.4±6.9. For hypertonic saline, LOS 1=7.0±7.3, LOS 
2=6.1±6.0, LOS 3=3.7±2.2, LOS 4=6.3±6.3. CONCLUSIONS: Our analysis shows a 
considerable of LOS variability by HN management and LOS definition. By 
correcting the analysis for baseline factors and outliers, the effect of HN 
management on LOS may become clearer.  
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OBJECTIVES: Real world data studies provide a level of granularity that may be 
not be available in randomized clinical trials (RCTs) that have strict inclusive 
exclusion criteria and may lead to weak external validity. Furthermore, RCTs 
generally do not capture important information on adherence, costs and rare 
side effects. The purpose of this study is to understand how to design patient 
registries and other observational studies to optimize their use to support 
market access decisions. METHODS: First, secondary research was conducted by 
analysing existing registries in a given therapeutic area in European markets 
including Belgium, Denmark, France, Germany, Italy, Poland, Spain, Sweden and 
the UK. Data points from existing registries were charted from ‘most’ to ‘least 
prevalent’. Missing attributes that were perceived as essential based on expert 
opinion were also collected, identifying gaps in available data. Second, an 
international payer panel completed a quantitative survey and completed 
primary in depth interviews to understand the relative impact of all the registry 
attributes, including those that were perceived as gaps. This included impact on 
price, reimbursement status and formulary listing. Transferability of data was 
also tested to identify whether payers would accept data from other markets and 
determine what should be collected to maximise market access. RESULTS: Data 
gaps were cross referenced with the payer needs to understand which endpoints 
are not currently being addressed. This allowed an accurate map of critical 
endpoints needed to have the greatest impact on market access. CONCLUSIONS: 
In an era of evidence based medicine and constrained budgets, drug 
manufacturers need to identify how to best utilise real world data and patient 
registries. Using this methodology, it is possible to identify what data to collect 
and where it should be collected in order to maximise the market access 
opportunity and pricing potential.  
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OBJECTIVES: Age-related dementia is a progressive degenerative brain syndrome 
whose prevalence increases with age. Alzheimer disease (AD), Parkinson disease 
(PD), Vascular Dementia (VD) are the most common age-related dementias. 
Dementias cause a substantial burden on society and on families who provide 
informal care. This study aims to review the relevant papers to compare 
informal care time and costs in different age-related dementias. METHODS: A 
systematic bibliographic search was performed on an international medical 
literature database (MEDLINE). All studies which assessed the social economic 
burden of different dementias were selected. Informal care time and costs were 
analyzed by disease stages and in three care settings, at home, in institution and 
without care setting distinction. RESULTS: 21 studies met our criteria. Depending 
on studies, informal costs vary from $1,364 to $44,736 in AD patients at home 
and from $1,563 to $5,386 in PD patients at home. Informal care time vary from 
11,59h to 139,30h per week for AD patient at home and from 10,00h to 22,00h per 
week for PD patients at home. For informal care time and costs in institution 
only papers on AD were available. The annual informal costs vary from $416 to 
$5,542 and informal care time varies from 3.02h to 17.25h per week. For patients 
without distinction of care setting, annual informal costs varies from $1,831to 
$11,251 for AD and informal care time from 12,29h to 66,55h per week. Mean 
informal care time per week for patient at home was 55.73 h in AD and 15.8 h in 
PD (p=0.0076) and the associated mean annual informal costs were $17,492 
versus $3,284, respectively (p=0.0393). CONCLUSIONS: There is a lack of data 
about informal care time and costs among other dementias than AD or PD. 
Globally, AD is most costly in terms of informal care costs than PD.  
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OBJECTIVES: The use of effective but high cost interventions and improved 
survival may affect the cost of a hospital admission. Thus, hospital costs for AIS 
may be expected to increase more than the average cost of medical care, as 
measured by the CPI, as the mix of cases change. The purpose of the study was 
to compare the actual trends in costs and charges for hospital admissions for AIS 
with the CPI, both overall and by use of tPA and mechanical thrombectomy (MT). 
METHODS: A total of 499,661 hospital admissions for AIS were extracted from 
the Nationwide Inpatient Sample (NIS), Healthcare Cost and Utilization Project 
(HCUP) data for 2005-2010. Cost per admission was estimated from total charges 
using each hospital’s cost-to-charge ratio and were compared with CPI trends in 
changes in health care costs provided by the US Bureau of Labor and Statistics. 
Use of tPA and/or MT was examined using multiple regression analyses. 
RESULTS: Cost of an acute care admission for AIS increased at a greater rate, 
annually, than the CPI from 2005 through 2008, but appeared to level of in 2009, 
with tPA admission most closely following the CPI. Utilization of tPA increased in 
2005 from 1.84% to 5.47% in 2010. The number of admissions with MT increased 
from 0.87% to 8.09% over the same time period. Charges for AIS admissions have 
increased much more rapidly than the CPI observed from 2005 to 2010, with 
admissions receiving tPA having the greatest gain in charges. CONCLUSIONS: 
Cost of care for AIS patients who receive tPA follows the CPI trend, while costs 
for non-tPA patients increase at a greater rate. This disparity could indicate a 
widening gap between cost and reimbursement for non-tPA admissions, and/or a 
failure of many hospitals to accurately record the use of tPA for billing purposes.  
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OBJECTIVES: To review published cost-utility analyses (CUA) targeted towards 
Asian populations and to understand the cost-effectiveness of the interventions 
studied. METHODS: We used the Tufts Medical Center Cost-Effectiveness 
Analysis Registry (www.cearegisty.org) to identify English-language CUAs 
pertaining to Asian countries published from 2000-2011. We examined 
prevention stage, type of interventions, and disease areas associated with 
“favorable” ratios, which we defined ratios less than the median of all 
incremental cost-effectiveness ratios (ICERs, expressed as $US2011 per QALY) in 
Asian CUAs. RESULTS: Of 2,717 CUAs published during 2000-2011, 109 (4.0%) 
pertained to Asian countries: Japan (n=43), Taiwan (n=23), China (n=11), 
